James E. Fickenscher
2017 - Zynerba Pharmaceuticals
In 2017, James E. Fickenscher earned a total compensation of $932.1K as Chief Financial Officer and Vice President, Corporate Development at Zynerba Pharmaceuticals, a 28% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $132,848 |
|---|---|
| Option Awards | $392,382 |
| Salary | $368,000 |
| Other | $38,894 |
| Total | $932,124 |
Fickenscher received $392.4K in option awards, accounting for 42% of the total pay in 2017.
Fickenscher also received $132.8K in non-equity incentive plan, $368K in salary and $38.9K in other compensation.
Rankings
In 2017, James E. Fickenscher's compensation ranked 9,296th out of 14,666 executives tracked by ExecPay. In other words, Fickenscher earned more than 36.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,296 out of 14,666 | 37th |
Division Manufacturing | 3,573 out of 5,768 | 38th |
Major group Chemicals And Allied Products | 1,227 out of 2,074 | 41st |
Industry group Drugs | 986 out of 1,730 | 43rd |
Industry Pharmaceutical Preparations | 775 out of 1,329 | 42nd |
Source: SEC filing on April 23, 2018.
Fickenscher's colleagues
We found two more compensation records of executives who worked with James E. Fickenscher at Zynerba Pharmaceuticals in 2017.
News
Zynerba Pharmaceuticals CEO Armando Anido's 2022 pay slips 15% to $1.9M
April 21, 2023
Zynerba Pharmaceuticals CEO Armando Anido's 2021 pay jumps 49% to $2.2M
April 25, 2022
Zynerba Pharmaceuticals CEO Armando Anido's 2020 pay rises 8% to $1.5M
April 21, 2021
Zynerba Pharmaceuticals CEO Armando Anido's 2019 pay falls 32% to $1.4M
April 23, 2020
Zynerba Pharmaceuticals CEO Armando Anido's 2018 pay slips 18% to $2M
April 25, 2019